Skip to main
NTHI

NTHI Stock Forecast & Price Target

NTHI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeOnc Technologies Hldgs is well-positioned for success in the biotech industry, with a strong focus on addressing unmet needs in CNS tumor treatment, a promising drug pipeline, and a solid financial outlook. The company's approach to using a natural compound like POH and developing novel agents shows a commitment to innovative solutions. Additionally, their reported positive financials and funding until 2026 provide a stable foundation for continued growth and expansion. With a potential for accelerated approval and a promising mechanism of action, NeOnc's drugs have the potential to make a significant impact on the lives of patients with CNS tumors and their ultimate goal aligns with the needs of the market.

Bears say

NeOnc Technologies Hldgs is facing several key challenges that could impact its success in the competitive biopharmaceutical industry. These include potential commercial and political risks that could lead to higher prices for its potentially lifesaving treatments, as well as technical risk related to the distribution of its drug in the central nervous system. In addition, concerns around the potential long-term safety and tolerability of its lead product candidates, NEO100 and NEO212, could lead to increased scrutiny and potential limited use of these therapies, limiting the company's potential for success in the market.

NTHI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neonc Technologies Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neonc Technologies Holdings Inc (NTHI) Forecast

Analysts have given NTHI a Strong Buy based on their latest research and market trends.

According to 3 analysts, NTHI has a Strong Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neonc Technologies Holdings Inc (NTHI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.